A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 8,241,000 cases in 2023. These cases are projected to increase during the forecast period, i.e., ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

-- Curium's Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...